BioNTech SE Stock price

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2023-12-06 pm EST Intraday chart for BioNTech SE 5-day change 1st Jan Change
101.34 USD +2.63% +2.11% -32.54%
Sales 2023 * 4.24B 4.56B Sales 2024 * 4.01B 4.31B Capitalization 22.32B 24.02B
Net income 2023 * 1.06B 1.14B Net income 2024 * 625M 673M EV / Sales 2023 *
1,16x
Net cash position 2023 * 17.4B 18.73B Net cash position 2024 * 18.36B 19.76B EV / Sales 2024 *
0,99x
P/E ratio 2023 *
21,5x
P/E ratio 2024 *
39,2x
Employees 5,700
Yield 2023 *
-
Yield 2024 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.63%
1 week+2.11%
Current month+0.93%
1 month+1.63%
3 months-15.59%
6 months-7.75%
Current year-32.54%
More quotes
1 week
94.70
Extreme 94.7
102.51
1 month
94.70
Extreme 94.7
103.41
Current year
88.00
Extreme 88.0001
156.28
1 year
88.00
Extreme 88.0001
188.99
3 years
80.55
Extreme 80.55
464.00
5 years
12.53
Extreme 12.525
464.00
10 years
12.53
Extreme 12.525
464.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 2008
Founder 56 2008
Director of Finance/CFO 59 2021
Members of the board TitleAgeSince
Director/Board Member 66 2008
Chairman 53 2008
Director/Board Member 62 2017
More insiders
Date Price Change Volume
23-12-06 101.34 +2.63% 810,326
23-12-05 98.74 -1.17% 800,594
23-12-04 99.91 +0.51% 823,208
23-12-01 99.4 -1.01% 802,924
23-11-30 100.41 +1.17% 658,831

Delayed Quote Nasdaq, December 06, 2023 at 04:00 pm EST

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
93.89EUR
Average target price
123.77EUR
Spread / Average Target
+31.82%
Consensus
1st Jan change Capi.
-32.54% 24 090 M $
+22.40% 91 081 M $
+15.84% 88 879 M $
-5.98% 31 581 M $
+22.60% 27 228 M $
-24.35% 21 026 M $
-17.26% 18 954 M $
+0.03% 11 738 M $
+22.68% 11 133 M $
-32.57% 8 174 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock BioNTech SE - Nasdaq
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer